A series of defeats by domestic pharmaceuticals in patent challenges

Domestic pharmaceutical companies were defeated from patent suits in series. They were against substance patents of Ezetrol(ezetimibe), Forxiga(dapagliflozin) and Pradaxa(dabigatran etexilate) and a crystalline patent of Suglat(ipragliflozin), but they all went in vain on the last 22^nd.

The industry sees it as a phenomenon that a number of pharmaceutical companies were driven to the patent su...